• Fujian Haixi Pharmaceuticals flagged the exit of non-executive director Wang Xinkun, effective when a new director is elected at a general meeting.
• The board nominated Chen Tingze as an executive director, with the mandate starting upon shareholder election.
• Chen has served as sales director and general manager for domestic marketing since March 2022.
• His prior roles include sales and marketing posts at GlaxoSmithKline China, Hisun-Pfizer, and Chengdu Kanghong Pharmaceutical.
• Chen holds interests in two venture capital partnerships that together own about 10.68% of the company’s share capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245367), on July 15, 2026, and is solely responsible for the information contained therein.